Attovia Therapeutics, Inc. Common Stock (ATTO NASDAQ) stock market data APIs
$25.677
-1.08(-4.2%)
as of September 4, 2026
Try our APIs with
free plan!
Attovia Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Prev. Close
25.677
Open
24.5951
High
27.5713
Low
24.5227
52 wk Range
16.15-27.66
Market Cap
1 166 M
Shares Outstanding
45 651 K
Revenue
1 800 K
EPS
-4.88
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Attovia Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Attovia Therapeutics, Inc. Common Stock Fundamental Data
Attovia Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue: 1 800 K
- EBITDA: -75 251 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Attovia Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-09-02
- EPS/Forecast: -4.61
Get Attovia Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Attovia Therapeutics, Inc. Common Stock News
New
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls tha...
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
Pre-Market Stock Futures: Futures are trading lower as we prepare to wrap up the summer months and head into the Labor Day long weekend holiday. All the major indices closed lower on Friday, but the ...
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Photo by geralt on Pixabay Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue. Moderna (MRNA) has returned abo...
Moderna Stock Had A Readout Waiting In Plain Sight
Photo by geralt on Pixabay Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move Moderna...
Get Attovia Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
